Please use this identifier to cite or link to this item:
https://doi.org/10.1081/IMM-120022979
DC Field | Value | |
---|---|---|
dc.title | Effects of Ganopoly® (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients | |
dc.contributor.author | Gao, Y. | |
dc.contributor.author | Zhou, S. | |
dc.contributor.author | Jiang, W. | |
dc.contributor.author | Huang, M. | |
dc.contributor.author | Dai, X. | |
dc.date.accessioned | 2014-10-29T01:52:09Z | |
dc.date.available | 2014-10-29T01:52:09Z | |
dc.date.issued | 2003 | |
dc.identifier.citation | Gao, Y., Zhou, S., Jiang, W., Huang, M., Dai, X. (2003). Effects of Ganopoly® (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunological Investigations 32 (3) : 201-215. ScholarBank@NUS Repository. https://doi.org/10.1081/IMM-120022979 | |
dc.identifier.issn | 08820139 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/105896 | |
dc.description.abstract | Preclinical studies have established that the Ganoderma lucidum polysaccharide (GLPS) fractions have potent anti-tumor activity, which has been associated with the immuno-stimulating effects of GLPS. However, it is unclear whether GLPS has immuno-modulating effects in humans in vivo. This study aimed to investigate the effects of Ganopoly®, the polysaccharides fractions extracted from G. lucidum, on the immune function of advanced-stage cancer patients. Thirty-four advance-stage cancer patients were entered onto this study, and treated with 1800 mg Ganopoly®, three times daily orally before meals for 12 weeks. Immune parameters (cytokines, T cell subsets, mitotic response to phytohemagglutinin (PHA) and natural killer (NK) activity) were compared between baseline and after 12-week treatment. Thirty patients are assessable for their immune functions. Treatment of Ganopoly® for 12 weeks resulted in a significant (P < 0.05) increase in the mean plasma concentrations of interleukin (IL-2), IL-6, and interferon (IFN)-γ, whereas the levels of IL-1 and tumor necrosis factor (TNF-α) were significantly (P < 0.05) decreased. A marked variability among patients with advanced-stage cancer was observed in the numbers of each lymphocyte subset at baseline. The mean absolute number of CD56+ cells was significantly (P < 0.05) increased after 12-week treatment of Ganopoly®, whereas the numbers of CD3+, CD4+, and CD8+ were just marginally increased compared to baseline levels, with the CD4:CD8 T cell ratios unchanged. PHA responses after 12-week treatment with Ganopoly® were enhanced in most patients, when compared to pretreatment baselines (P < 0.05). In addition, Ganopoly® treatment resulted in a significant increase (P < 0.05) in the mean NK activity compared to baselines (34.5 ± 11.8% vs 26.6 ± 8.3%). The present study indicates that Ganopoly® enhanced the immune responses in patients with advanced-stage cancer. Clinical evaluations of response and toxicity are ongoing. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1081/IMM-120022979 | |
dc.source | Scopus | |
dc.subject | Efficacy | |
dc.subject | Ganoderma lucidum | |
dc.subject | Polysaccharide | |
dc.subject | Safety | |
dc.subject | Tumor | |
dc.type | Article | |
dc.contributor.department | PHARMACY | |
dc.description.doi | 10.1081/IMM-120022979 | |
dc.description.sourcetitle | Immunological Investigations | |
dc.description.volume | 32 | |
dc.description.issue | 3 | |
dc.description.page | 201-215 | |
dc.description.coden | IMINE | |
dc.identifier.isiut | 000184515500007 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.